Top

Published in:

01-07-2007 | Case Report

Polymyositis complicating donor lymphocyte infusion after stem cell transplantation for relapsed chronic myeloid leukemia: report of a case and review of literature

Authors: Feng-Cheng Liu, Chen-Hung Chen, Tsu-Yi Chao

Published in: Clinical Rheumatology | Issue 7/2007

Abstract

Polymyositis may occur along with other manifestations of chronic graft vs host disease after allogeneic bone marrow transplantation (BMT). Donor lymphocyte infusion (DLI) could produce durable remissions in relapsed patients with chronic myelogenous leukemia (CML) but it may contribute to the development of polymyositis. We report in this study a 25-year-old man who suffered from a relapse of CML 4 years after a sibling human leukocyte antigen-matched allogenic BMT. The patient developed polymyositis 18 months after DLI. Mini-pulse therapy with methylprednisolone was effective for his proximal weakness and elevated creatine phosphokinase. There was no relapse of symptoms of polymyositis on tapering of the medication.

Biju G, Debashis D, Mammen C, Alok S, Vikram M et al (2001) Polymyositis—an unusual manifestation of chronic graft-versus-host disease. Rheumatol Int 20:169–170CrossRef

Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsten N, Arcese W et al (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86:2041–2050PubMed

Tse S, Saunders EF, Silverman E, Vajsar J, Becker L, Meaney B (1999) Myasthenia gravis and polymyositis as manifestations of chronic GVHD. Bone Marrow Transplant 23:397–399PubMedCrossRef

Reyes M, Noronha P, Thomas W, Heredia R (1983) Myositis of chronic GVHD. Neurology 33:1222–1224PubMed

Adams C, August CS, Maguire H, Sladky JT (1995) Neuromuscular complications of bone marrow transplantation. Pediatr Neurol 12:58–61PubMedCrossRef

Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555PubMed

Moller E, Bohme J, Valugerdi MA, Ridderstad A, Olerup O (1990) Speculations on mechanisms of HLA associations with autoimmune diseases and the specificity of autoreactive T lymphocytes. Immunol Rev 118:5–19PubMedCrossRef

Couriel DR, Beguelin GZ, Giralt S, Lima MD, Hosing C, Kharfan-Dabaja MA (2002) Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation. Bone Marrow Transplant 30:543–546PubMedCrossRef

Megan S, Frederic P, Steven M, Susan L, Dina W, David W et al (1999) Mixed lymphohaemopoetic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone marrow transplantation. Lancet 353:1755–1759CrossRef

10.

Pier N, Dubowitz V (1983) Chronic graft versus host disease presenting with polymyositis. Br Med J 286:2024CrossRef

11.

Leber B, Warlker IR, Rodriguez A, McBride JA, Carter R, Brain MC et al (1993) Reinduction of remission of chronic myeloid leukemia by donor leukocyte transfusion following relapse after bone marrow transplantation: recovery complicated by initial pancytopenia and late dermatomyositis. Bone Marrow Transplant 12:405–407PubMed

12.

Y Oshima, S Takahashi, H Nagayama, K Nishiwaki, Y Kobayashi, A Tojo et al (1997) Fatal GVHD demonstrating an involvement of respiratory muscle following donor leukocyte transfusion (DLT). Bone Marrow Transplant 19:737–740PubMedCrossRef

13.

Silberstein L, Davies A, Kelsey S, Foran J, Murrell C, D’Cruz D et al (2001) Myositis, polyserositis with a large pericardial effusion and constrictive pericarditis as manifestations of chronic graft-versus-host disease after non-myeloablative peripheral stem cell transplantation and subsequent donor lymphocyte infusion. Bone Marrow Transplant 27:231–233PubMedCrossRef

14.

Lin P-C, Hsiao L-T, Chen P-M (2005) Acute polymyositis after donor lymphocyte infusion. Eur J Haematol 74:166–168PubMedCrossRef

Title: Polymyositis complicating donor lymphocyte infusion after stem cell transplantation for relapsed chronic myeloid leukemia: report of a case and review of literature
Authors: Feng-Cheng Liu
Chen-Hung Chen
Tsu-Yi Chao
Publication date: 01-07-2007
Publisher: Springer-Verlag
Published in: Clinical Rheumatology / Issue 7/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-006-0346-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2007

Rheumatoid arthritis is linked to Proteus—the evidence

The dynamism of cutaneous lupus erythematosus: mild discoid lupus erythematosus evolving into SLE with SCLE and treatment-resistant lupus panniculitis

Vasculitis in siblings with familial Mediterranean fever: a report of three cases and review of the literature

Liposynovitis prepatellaris in athletic runner (Hoffa's syndrome): case report and review of the literature

Meta-analysis is no substitute for a comprehensive national registry

The effect of infliximab on chemokines in patients with rheumatoid arthritis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials